Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by B.O.S.S. Retirement Advisors LLC

B.O.S.S. Retirement Advisors LLC trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 93.8% in the fourth quarter, Holdings Channel reports. The firm owned 635 shares of the medical research company’s stock after selling 9,585 shares during the quarter. B.O.S.S. Retirement Advisors LLC’s holdings in Thermo Fisher Scientific were worth $330,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of TMO. AQR Capital Management LLC boosted its stake in Thermo Fisher Scientific by 18.1% in the second quarter. AQR Capital Management LLC now owns 98,152 shares of the medical research company’s stock valued at $54,278,000 after acquiring an additional 15,009 shares during the period. Daymark Wealth Partners LLC boosted its stake in Thermo Fisher Scientific by 24.5% in the second quarter. Daymark Wealth Partners LLC now owns 619 shares of the medical research company’s stock valued at $342,000 after acquiring an additional 122 shares during the period. MBB Public Markets I LLC boosted its stake in Thermo Fisher Scientific by 767.0% in the second quarter. MBB Public Markets I LLC now owns 29,278 shares of the medical research company’s stock valued at $16,191,000 after acquiring an additional 25,901 shares during the period. Lummis Asset Management LP boosted its position in shares of Thermo Fisher Scientific by 1.2% during the second quarter. Lummis Asset Management LP now owns 3,030 shares of the medical research company’s stock worth $1,676,000 after buying an additional 37 shares during the period. Finally, Lighthouse Investment Partners LLC boosted its position in shares of Thermo Fisher Scientific by 91.3% during the second quarter. Lighthouse Investment Partners LLC now owns 10,892 shares of the medical research company’s stock worth $6,023,000 after buying an additional 5,199 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $575.21 on Friday. The company’s fifty day moving average is $533.60 and its two-hundred day moving average is $569.32. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 12-month low of $493.30 and a 12-month high of $627.88. The company has a market cap of $220.02 billion, a P/E ratio of 36.06, a price-to-earnings-growth ratio of 3.82 and a beta of 0.76.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The company had revenue of $10.60 billion for the quarter, compared to the consensus estimate of $10.63 billion. During the same period in the previous year, the business earned $5.69 EPS. The company’s revenue was up .2% on a year-over-year basis. Equities analysts expect that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its board has approved a stock repurchase plan on Friday, November 15th that authorizes the company to buyback $4.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to purchase up to 2% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s leadership believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th were issued a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. The ex-dividend date was Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio is currently 9.78%.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the transaction, the chief executive officer now directly owns 111,192 shares in the company, valued at $58,960,669.92. The trade was a 8.25 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold a total of 44,850 shares of company stock worth $24,666,097 in the last ninety days. Corporate insiders own 0.34% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on TMO shares. Wells Fargo & Company reduced their price objective on Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. Sanford C. Bernstein upgraded Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price objective for the company in a research report on Friday, January 10th. Scotiabank assumed coverage on Thermo Fisher Scientific in a research report on Monday, December 23rd. They set a “sector perform” rating and a $605.00 price objective for the company. Robert W. Baird dropped their target price on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Finally, Morgan Stanley dropped their target price on Thermo Fisher Scientific from $670.00 to $647.00 and set an “overweight” rating on the stock in a report on Monday, January 13th. Four research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $648.95.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.